Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $17.27

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $17.27, but opened at $16.20. Calliditas Therapeutics AB (publ) shares last traded at $16.80, with a volume of 2,207 shares traded.

Wall Street Analyst Weigh In

CALT has been the subject of a number of research analyst reports. HC Wainwright decreased their price target on Calliditas Therapeutics AB (publ) from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, August 21st. Guggenheim dropped their price target on Calliditas Therapeutics AB (publ) from $21.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, August 18th.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a market capitalization of $492.13 million, a PE ratio of -16.15 and a beta of 1.56. The firm has a 50-day moving average of $17.27 and a two-hundred day moving average of $19.66. The company has a quick ratio of 3.77, a current ratio of 3.84 and a debt-to-equity ratio of 1.55.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its earnings results on Thursday, August 17th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.08). The firm had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $28.34 million. Calliditas Therapeutics AB (publ) had a negative net margin of 25.68% and a negative return on equity of 44.80%. Research analysts anticipate that Calliditas Therapeutics AB will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A number of institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its position in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after buying an additional 3,112 shares in the last quarter. Jane Street Group LLC purchased a new position in Calliditas Therapeutics AB (publ) during the first quarter valued at $221,000. Ironwood Investment Management LLC lifted its holdings in Calliditas Therapeutics AB (publ) by 5.6% during the first quarter. Ironwood Investment Management LLC now owns 27,795 shares of the company’s stock valued at $666,000 after purchasing an additional 1,486 shares in the last quarter. Finally, Deutsche Bank AG grew its position in shares of Calliditas Therapeutics AB (publ) by 26.5% in the first quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after purchasing an additional 18,978 shares during the period. 2.95% of the stock is currently owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.